| Recruitment status | Recruiting |
| Unique ID issued by UMIN | UMIN000025469 |
| Receipt No. | R000029292 |
| Official scientific title of the study | Effect of gastric acid suppression by use of vonoplazan |
| Date of disclosure of the study information | 2016/12/31 |
| Last modified on | 2017/01/06 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Effect of gastric acid suppression by use of vonoplazan | |
| Title of the study (Brief title) | Effect of gastric acid suppression by use of vonoplazan | |
| Region |
|
|
| Condition | ||
| Condition | healthy person | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the effect of gastric acid suppression by use of vonoprazan |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Others |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | gastric acid secretion (1day before administration, 6 days in administration, 3days after administration) |
| Key secondary outcomes | Serum gastrin levels |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | administration of vonoprazan | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | (1)Healthy Japanese adult males.
(2)Between the ages of 20-45 at the time of informed consent. (3)Subjects signed informed consent form voluntary. |
|||
| Key exclusion criteria | (1)Subjects with history of gastric ulcer or duodenum ulcer
(2)Subjects with a serious complication of liver failure (3)Subjects with a serious complication of renal failure (4)Subjects with a serious complication of heart failure (5)Subjects treated with atazanavir sulfate (Reyataz) or rilpivirine hydrochloride (Edurant) (6)Subjects with Zollinger-Ellison syndrome (7)Subjects with history of surgery that affects gastric-acid secretion (8)Subjects with a history of allergy to the investigational product (9)Subjects with atrophic gastritis, gastric tumor, gastric ulcer or duodenum ulcer by endoscopic examination. |
|||
| Target sample size | 10 | |||
| Research contact person | |
| Name of lead principal investigator | Mototsugu Kato |
| Organization | National Hospital Organization Hakodate Hospital |
| Division name | Department of Gastroenterology and Hepatology |
| Address | 16-gou, 18-banchi, Kawahara-chou, Hakodate, 041-8512, Japan |
| TEL | +81-0138-51-6281 |
| mkato1957@gmail.com | |
| Public contact | |
| Name of contact person | Mototsugu Kato |
| Organization | National Hospital Organization Hakodate Hospital |
| Division name | Department of Gastroenterology and Hepatology |
| Address | 16-gou, 18-banchi, Kawahara-chou, Hakodate, 041-8512, Japan |
| TEL | +81-0138-51-6281 |
| Homepage URL | |
| mkato1957@gmail.com | |
| Sponsor | |
| Institute | National Hospital Organization Hakodate Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Eisai Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Daiichi Sankyo Co., Ltd.; and AstraZeneca K.K. and Astellas Pharma Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029292 |